(Q45046880)

8 December 2017

title

Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naïve patients (English)

1 reference

8 December 2017

1 reference

5

1 reference

8 December 2017

Eiichi Kodama

3

0 references

Hiroaki Mitsuya

7

object named as

Hiroaki Mitsuya

1 reference

8 December 2017

1

Atsuko Hachiya

1 reference

8 December 2017

2

Hiroyuki Gatanaga

1 reference

8 December 2017

Mieko Ikeuchi

4

1 reference

8 December 2017

Shigeyoshi Harada

6

1 reference

8 December 2017

Satoshi Kimura

8

1 reference

8 December 2017

Shinichi Oka

9

1 reference

8 December 2017

language of work or name

English

0 references

publication date

1 October 2004

1 reference

8 December 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

published in

Virology

1 reference

8 December 2017

volume

327

1 reference

8 December 2017

issue

2

1 reference

8 December 2017

page(s)

215-224

1 reference

Thailand's Do-It-Yourself Therapy

8 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

Active HIV-1 redistribution and replication in the brain with HIV encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

Time trends in primary HIV-1 drug resistance among recently infected persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

"All-in-One Assay", a direct phenotypic anti-human immunodeficiency virus type 1 drug resistance assay for three-drug combination therapies that takes into consideration in vivo drug concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

HIV type 1 V3 variation dynamics in vivo: long-term persistence of non-syncytium-inducing genotypes and transient presence of syncytium-inducing genotypes during the course of progressive AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

Antiretroviral-drug resistance among patients recently infected with HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

Prevention of Mother-to-Child Transmission of HIV-What Next?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.001

10.1016/J.VIROL.2004.07.001

7 January 2021

Identifiers

DOI

1 reference

8 December 2017

1 reference